LYEL: Lyell Immunopharma, Inc. Common Stock Company Profile & Statistics

Lyell Immunopharma, Inc. Common Stock Profile

About

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

Info & Links

CEO

Lynn Seely

Headquarters

201 HASKINS WAY
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

300

Lyell Immunopharma, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

316.79M

Enterprise Value

217.99M

Enterprise Value/EBITDA(ttm)

-0.62

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

5.35K

Price to Book(mrq)

0.86

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-552328.31%

Profit Margin(ttm)

-788795.80%

Return on Equity(ttm)

-85.58%

Return on Invested Capital(ttm)

-88.33%

Return on Assets(ttm)

-68.85%

Income Statement

Revenue(ttm)

60.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

60.00K

EBITDA(ttm)³

-349.32M

Net Income Available to Common(ttm)

-331.40M

Diluted EPS(ttm)

-24.29

Share Statistics

Beta (5Y Monthly)

-0.07

52-Week Change

-13.04%

S&P 500 52-Week Change

19.58%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

19.21M

Dividend Yield

0.00%

Float⁴

14.93M

% Held by Insiders

22.30%

% Held by Institutions

66.05%

Balance Sheet

Total Cash(mrq)

276.79M

Total Cash Per Share(mrq)

14.41

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

7.65%

Quick Ratio(mrq)

7.65%

Book Value Per Share(mrq)

20.16

Cash Flow

Operating Cash Flow Per Share(ytd)

-6.03

Free Cash Flow(ytd)

-89.61M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

LYEL

Lyell Immunopharma, Inc. Common Stock